Breast Cancer Clinical Trial
Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography
Summary
This was a multi-center, prospective clinical trial in which the subject was her own control. Approximately 950-1400 female subjects were enrolled at five (5) sites in the United States. Subjects were from either a Screening population or a biopsy population and were imaged first on a conventional 2D full filed digital mammography system then on a 3D tomosynthesis system.
The resulting images from the this portion of the study were then randomized into a reader study.
The purpose of this clinical study was to compare the 3-D tomosynthesis system used in conjunction with a conventional 2-D digital imaging system (2-D plus 3-D images) to the conventional 2-D digital imaging system (2-D images), and to determine whether the 2-D plus 3-D images compared to the 2-D images alone would:
Reduce the recall rate And/or
Improve ROC area due to improved breast cancer detection and/or improved lesion classification.
Eligibility Criteria
Inclusion Criteria:
Female
Any ethnic origin
No contraindication for screening mammography
Exclusion Criteria:
Significant breast trauma
Pregnancy
Lactating
Breast implants
Previous breast cancer
Previous surgical biopsy
Placement of an internal breast marker
Unable to understand and or execute written informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
New Haven Connecticut, 06520, United States
Iowa City Iowa, 52242, United States
Boston Massachusetts, 02116, United States
Lebanon New Hampshire, 03756, United States
Pittsburgh Pennsylvania, 15213, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.